RenaSci Manuscript Publication List
2009
The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009; 57:608-18.
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology 2009; 68:861-874.
Receptor Occupancy and Brain Free Fraction. Drug Metabolism and Disposition 2009; 37:753–760.
2008
Selective 5-HT6 ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacology & Therapeutics 2008;117:207-231.
New perspectives from microdialysis studies in freely moving spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 2008;90:184-197.
2007
The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology 2007;194:221-231.
GPR39 signalling is stimulated by zinc ions but not by obestatin. Endocrinology 2007;148:13-20.
Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol 2007;74:1292-8.
Preclinical developments in antiobesity drugs. In: Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs, Eds T Kirkham and S Cooper, Academic Press
pp323-336, 2007.
2006
The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. Diabetes Vasc Dis Res 2006;3:186-188.
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006;148:1-11.
Obesity Drug Development – CBI’s 2nd Annual Summit. IDrugs 2006;9:682 685.
Methylphenidate and its isomers. Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006;20(9):713-738.
Differential effects of d- and l threo methylphenidate on extracellular levels of dopamine in the striatum and noradrenaline in the frontal cortex: a dual probe microdialysis study in freely moving spontaneously hypertensive rats. In Monitoring Molecules in Neuroscience, Proceedings of the 11th International Conference on In Vivo Methods. Di Chiara G, Carboni E, Valentini V, Acquas E, Bassareo V, Cadoni C (Eds), University of Cagliari, Italy pp 499 501.
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3(3):167-75.
The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. Horm Metab Res 2006;38:727-731.
Does contraversive circling in the –OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson’s disease? Exp. Neurology 197, 284-290, 2006.
2005
Development, Regulatory and Marketing challenges for novel anitobesity therapies. In Obesity and Metabolic Disorders. J Antel, N Finer, D Heal, G Krause (Eds), IOS Press 2005, pp. 73-91.
KTX 0101: a potential metabolic approach to cytoprotection in major surgery and neurological disorders. CNS Drug Reviews 2005;11(2):113-140.
Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets. 2, 215-23, 2005.
Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours Eur. J. Neuroscience 21:179-186, 2005.
2004
Novel Targets for the treatment of obesity: a review of progress. Drug Discovery Today 2004;1(2):227-235.
Ingestive behaviour in rodents: model systems applicable to main for evaluating drug action. ESSWAP Meeting, August 2004.
5 HT has contrasting effects in the frontal cortex, but not the hypothalamus, on changes in noradrenaline efflux induced by the monoamine releasing agent, d amphetamine, and the reuptake inhibitor, BTS 54 354. Neuropharmacol 2004;46:511 518.
Pharmacological characterization of the thermogenic effect of bupropion. Eur J Pharmacol 2004;498:219 225.
Acute cardiovascular effects of sibutramine in conscious rats. J Pharm Exp Ther 2004;308:1102 1110.
Serotonin receptor ligands and the treatment of obesity. Curr Opin Investig Drugs. 4, 377-88, 2004.
2003
Noradrenaline clearance differs in the frontal cortex and hypothalamus: a dual probe microdialysis study in freely moving rats. Neurosci Lett 2003;350:157 160.
Differences in the mechanisms that increase noradrenaline efflux after administration of
d-amphetamine: a dual probe microdialysis study in rat frontal cortex and hypothalamus.
Br. J. Pharmac, 139, 1441-1448, 2003
Delivering the next generation of anti obesity therapies – challenges for pharmacogenomics, patients and the pharmaceutical industry. In Progress in Obesity Research. G Medeiros-Neto, A Halpern, C Bouchard (Eds), John Libby Eurotext Ltd 2003, pp. 260-264.
2002
Acute stimulation of glucose uptake by leptin in L6 muscle cells. Horm Metab Res 2002;34:111-115.
Antibody induced lysis of isolated rat epididymal adipocytes and complement activation in vivo. Obesity Research 2002;10(2):122-127.
Artifactual uncoupling by uncoupling protein 3 in yeast mitochondria at the concentrations found in mouse and rat skeletal muscle mitochondria. Biochem J. 2002;361:49-56.
Comparison of the thermogenic and hyperphagic effects of sibutramine’s Metabolite 2 and other monoamine reuptake inhibitors. Eur J Pharmacol 2002;452:49 56.
Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti obesity drug, sibutramine. Int J Obes 2002;26:1245 1253.
Effects on serotonin in rat hypothalamus of d fenfluramine, aminorex, phentermine and fluoxetine. Eur J Pharmacol 2002;445:69-81.
2001
Sibutramine metabolites increase glucose transport by cultured rat muscle cells IJO 2001;25:478-485.
Determination of body composition in conscious adult female Wistar rats utilising total body electrical conductivity. Physiology & Behaviour 2001;74:425-433.
Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obesity Reviews 2001;2:255-265.
Edited books
“Obesity and Metabolic Disorders”. Solvay Pharmaceuticals Conferences Series, Volume 4, Amsterdam, 2005.